Clinicn Investigator, Assc Prf Neurology, Mass General Research Institute

Associate Professor of Neurology Harvard Medical School

Associate Neurologist Neurology, Massachusetts General Hospital

MD Columbia University College of Physicians & Surgeons 2001

MPH 2009

antiparkinson agents; biomarker studies; body mass index; clinical trials as topic; corticobasal ganglionic degeneration; environmental risk factors; multiple system atrophy; neurodegenerative disease; parkinson's disease; patient reported outcomes; progressive supranuclear palsy; psp; tauopathies Dr. Wills is the Director of the CurePSP Center of Care at Massachusetts General Hospital.  She has clinical expertise in Movement Disorders including PSP, DLB and PD, formal training in clinical trial design and implementation, and experience designing innovative clinical trials using remote data collection. She is the co-PI of the multicenter Progressive Supranuclear Palsy Clinical Trial Platform (PTP) (R01 AG085029) and the multi-center Multi-Modal Remote Monitoring Platform for Frontotemporal Lobar Degeneration Syndromes (SBIR 1R44AG080861) focused upon novel digital biomarkers for PSP.  She also has extensive experience in Parkinson's disease clinical trials and is on the steering committee for the Parkinson's Foundation PD Generation study.  She is the co-founder of the Atypical Parkinsonian disorders working group of the Parkinson’s Study Group, serves on the Scientific Advisory Board of the FTD Registry, the PSP Task Force of the Critical Path Institute, and serve on the Steering Committee of the PSP Study Group of the International Parkinson and Movement Disorder Society.